Eloxx Pharmaceuticals ( (ELOX) ) has released a notification of late filing.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Eloxx Pharmaceuticals has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to ongoing financial constraints that prevent the company from engaging its independent public accounting firm to review its unaudited financial statements. Eloxx Pharmaceuticals has not provided a specific timeline for when the delayed report will be filed. The company anticipates a significant increase in net loss and accumulated deficit for the quarter ended June 30, 2025, compared to the same period in the previous year. Additionally, there is substantial doubt about the company’s ability to continue as a going concern due to insufficient cash resources. The notification was signed by Sumit Aggarwal, the President and CEO, on August 14, 2025, indicating the company’s commitment to resolving these issues and maintaining compliance.
More about Eloxx Pharmaceuticals
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3
See more data about ELOX stock on TipRanks’ Stock Analysis page.